-DOCSTART- -X- O
INTRODUCTION -X- _ O
: -X- _ O
Patients -X- _ O
with -X- _ O
severe -X- _ O
acute -X- _ O
exacerbations -X- _ O
of -X- _ O
asthma -X- _ O
often -X- _ O
receive -X- _ O
inappropriate -X- _ O
antibiotic -X- _ O
treatment. -X- _ O
We -X- _ O
aimed -X- _ O
to -X- _ O
determine -X- _ O
whether -X- _ O
serum -X- _ B-Intervention
procalcitonin -X- _ I-Intervention
( -X- _ I-Intervention
PCT -X- _ I-Intervention
) -X- _ I-Intervention
levels -X- _ I-Intervention
can -X- _ O
effectively -X- _ O
and -X- _ O
safely -X- _ O
reduce -X- _ O
antibiotic -X- _ B-Comparison
exposure -X- _ I-Comparison
in -X- _ O
patients -X- _ B-Patient
experiencing -X- _ I-Patient
exacerbations -X- _ I-Patient
of -X- _ I-Patient
asthma. -X- _ I-Patient
METHODS -X- _ O
: -X- _ O
In -X- _ O
this -X- _ O
randomized -X- _ O
controlled -X- _ O
trial -X- _ O
, -X- _ O
a -X- _ O
total -X- _ O
of -X- _ O
216 -X- _ O
patients -X- _ O
requiring -X- _ O
hospitalization -X- _ O
for -X- _ O
severe -X- _ O
acute -X- _ O
exacerbations -X- _ O
of -X- _ O
asthma -X- _ O
were -X- _ O
screened -X- _ O
for -X- _ O
eligibility -X- _ O
to -X- _ O
participate -X- _ O
and -X- _ O
169 -X- _ O
completed -X- _ O
the -X- _ O
12-month -X- _ O
follow-up -X- _ O
visit. -X- _ O
Patients -X- _ O
were -X- _ O
randomized -X- _ O
to -X- _ O
either -X- _ O
PCT-guided -X- _ B-Intervention
( -X- _ I-Intervention
PCT -X- _ I-Intervention
group -X- _ I-Intervention
) -X- _ I-Intervention
or -X- _ O
standard -X- _ B-Comparison
( -X- _ I-Comparison
control -X- _ I-Comparison
group -X- _ I-Comparison
) -X- _ I-Comparison
antimicrobial -X- _ I-Comparison
therapy. -X- _ I-Comparison
In -X- _ O
the -X- _ O
control -X- _ O
group -X- _ O
, -X- _ O
patients -X- _ O
received -X- _ O
antibiotics -X- _ O
according -X- _ O
to -X- _ O
the -X- _ O
attending -X- _ O
physicianâ€™s -X- _ O
discretion -X- _ O
; -X- _ O
in -X- _ O
the -X- _ O
PCT -X- _ O
group -X- _ O
, -X- _ O
patients -X- _ O
received -X- _ O
antibiotics -X- _ O
according -X- _ O
to -X- _ O
an -X- _ O
algorithm -X- _ O
based -X- _ O
on -X- _ O
serum -X- _ O
PCT -X- _ O
levels. -X- _ O
The -X- _ O
primary -X- _ O
end -X- _ O
point -X- _ O
was -X- _ O
antibiotic -X- _ B-Comparison
exposure -X- _ I-Comparison
; -X- _ O
secondary -X- _ O
end -X- _ O
points -X- _ O
were -X- _ O
clinical -X- _ O
recovery -X- _ O
, -X- _ O
length -X- _ O
of -X- _ O
hospital -X- _ O
stay -X- _ O
, -X- _ O
clinical -X- _ O
and -X- _ O
laboratory -X- _ O
parameters -X- _ O
, -X- _ O
spirometry -X- _ O
, -X- _ O
number -X- _ O
of -X- _ O
asthma -X- _ O
exacerbations -X- _ O
, -X- _ O
emergency -X- _ O
room -X- _ O
visits -X- _ O
, -X- _ O
hospitalizations -X- _ O
and -X- _ O
need -X- _ O
for -X- _ O
corticosteroid -X- _ O
use -X- _ O
due -X- _ O
to -X- _ O
asthma. -X- _ O
RESULTS -X- _ O
: -X- _ O
PCT -X- _ B-Outcome
guidance -X- _ I-Outcome
reduced -X- _ I-Outcome
antibiotic -X- _ I-Outcome
prescription -X- _ I-Outcome
( -X- _ I-Outcome
48.9 -X- _ I-Outcome
% -X- _ I-Outcome
versus -X- _ I-Outcome
87.8 -X- _ I-Outcome
% -X- _ I-Outcome
, -X- _ I-Outcome
respectively -X- _ I-Outcome
; -X- _ I-Outcome
P -X- _ I-Outcome
< -X- _ I-Outcome
0.001 -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ O
antibiotic -X- _ B-Outcome
exposure -X- _ I-Outcome
( -X- _ I-Outcome
relative -X- _ I-Outcome
risk -X- _ I-Outcome
, -X- _ I-Outcome
0.56 -X- _ I-Outcome
; -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
confidence -X- _ I-Outcome
interval -X- _ I-Outcome
, -X- _ I-Outcome
0.44 -X- _ I-Outcome
to -X- _ I-Outcome
0.70 -X- _ I-Outcome
; -X- _ I-Outcome
P -X- _ I-Outcome
< -X- _ I-Outcome
0.001 -X- _ I-Outcome
) -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
standard -X- _ I-Outcome
therapy. -X- _ I-Outcome
There -X- _ O
were -X- _ O
no -X- _ B-Outcome
significant -X- _ I-Outcome
differences -X- _ I-Outcome
in -X- _ I-Outcome
clinical -X- _ I-Outcome
recovery -X- _ I-Outcome
, -X- _ I-Outcome
length -X- _ I-Outcome
of -X- _ I-Outcome
hospital -X- _ I-Outcome
stay -X- _ I-Outcome
or -X- _ I-Outcome
clinical -X- _ I-Outcome
, -X- _ I-Outcome
laboratory -X- _ I-Outcome
and -X- _ I-Outcome
spirometry -X- _ I-Outcome
outcomes -X- _ I-Outcome
in -X- _ O
both -X- _ O
groups. -X- _ O
Number -X- _ O
of -X- _ O
asthma -X- _ O
exacerbations -X- _ O
, -X- _ O
emergency -X- _ O
room -X- _ O
visits -X- _ O
, -X- _ O
hospitalizations -X- _ O
and -X- _ O
need -X- _ O
for -X- _ O
corticosteroid -X- _ O
use -X- _ O
due -X- _ O
to -X- _ O
asthma -X- _ O
were -X- _ O
similar -X- _ O
during -X- _ O
the -X- _ O
12-month -X- _ O
follow-up -X- _ O
period. -X- _ O
CONCLUSION -X- _ O
: -X- _ O
A -X- _ O
PCT-guided -X- _ O
strategy -X- _ O
allows -X- _ O
antibiotic -X- _ B-Comparison
exposure -X- _ I-Comparison
to -X- _ O
be -X- _ O
reduced -X- _ O
in -X- _ O
patients -X- _ O
with -X- _ O
severe -X- _ O
acute -X- _ O
exacerbation -X- _ O
of -X- _ O
asthma -X- _ O
without -X- _ O
apparent -X- _ O
harm. -X- _ O
TRIAL -X- _ O
REGISTRATION -X- _ O
: -X- _ O
Chinese -X- _ O
Clinical -X- _ O
Trial -X- _ O
Register -X- _ O
ChiCTR-TRC-12002534 -X- _ O
( -X- _ O
registered -X- _ O
26 -X- _ O
September -X- _ O
2012 -X- _ O
) -X- _ O

